Compare Kisqali vs. Kisqali Femara Co-Pack
Head-to-head comparisons of medication uses, side effects, warnings, and more.
- Kisqali (ribociclib)Kisqali femara co-pack
- Kisqali (ribociclib)Kisqali femara co-pack
Summary of Kisqali vs. Kisqali Femara Co-Pack
Summary for Cyclin-dependent kinase (CDK) inhibitorPrescription onlyKisqali (ribociclib) is a medication used to treat certain types of breast cancer, specifically hormone receptor–positive, human epidermal growth factor 2-negative (HR+, HER2-) breast cancer. It belongs to a drug class called CDK4/6 inhibitors, which help slow or stop cancer cells from growing. You typically take a tablet by mouth once a day for 21 days, then take 7 days off, repeating this 28-day cycle. It’s often taken together with other hormone treatments, like aromatase inhibitors or fulvestrant. Common side effects include feeling tired, nausea, and low white blood cell counts, which can make it easier to get infections.
Summary for Cyclin-dependent kinase (CDK) inhibitor / Aromatase inhibitorPrescription onlyKisqali Femara Co-Pack is a combination medication used to treat certain types of breast cancer, specifically hormone receptor–positive, human epidermal growth factor 2-negative (HR+, HER2-) breast cancer. It contains two medications: Kisqali (ribociclib), a CDK4/6 inhibitor, and Femara (letrozole), an aromatase inhibitor. You take Kisqali once a day for 21 days, then take 7 days off, in a 28-day cycle. Femara is taken once a day with no breaks. Common side effects include feeling tired, nausea, and low white blood cell counts, which can make it easier to get infections.
Indications of Kisqali vs. Kisqali Femara Co-Pack
Indications for•Early breast cancer (HR+, HER2-), used with an aromatase inhibitor in adults at high risk of the cancer coming back•Advanced or metastatic breast cancer (HR+, HER2-), used with•An aromatase inhibitor as the first hormone-based treatment OR•Fulvestrant either as the first treatment or after the cancer has stopped responding to hormone-based treatmentIndications for•Early breast cancer (HR+, HER2-) in adults at high risk of the cancer coming back•Advanced or metastatic breast cancer (HR+, HER2-) as the first hormone-based treatmentPros and Cons of Kisqali vs. Kisqali Femara Co-Pack
Pros and Const for Cyclin-dependent kinase (CDK) inhibitorPros•Taken by mouth once a day•A first-choice treatment option for HR+, HER2- breast cancer•Can be taken with or without foodCons•Common side effects include nausea, tiredness, and headache•Requires regular blood tests to monitor for side effects•Interacts with many medicationsPros and Const for Cyclin-dependent kinase (CDK) inhibitor / Aromatase inhibitorPros•Combines two medications in one package•Pills are taken by mouth•A first-choice treatment option for HR+, HER2- breast cancerCons•Common side effects include nausea, tiredness, and headache•Requires regular blood tests to monitor for side effects•Interacts with many medicationsCommon Side Effects of Kisqali vs. Kisqali Femara Co-Pack
Common Side Effects forEarly breast cancer
•Lower white blood cell counts (up to 97%)•Lower red blood cell counts (47%)•Higher liver enzymes (up to 45%)•Infections (37%)•Higher creatinine levels (33%)•Lower platelets (28%)•Headache (23%)•Nausea (23%)•Tiredness (22%)Advanced or metastatic breast cancer
•Lower white blood cell counts (up to 95%)•Lower red blood cell counts (68%)•Higher liver enzymes (up to 55%)•Nausea (47%)•Infections (47%)•Higher creatinine levels (42%)•Tiredness (35%)•Low red blood cell count•Lower appetite•Dizziness•Trouble sleeping•Trouble breathing•Swollen or sore mouth•Stomach pain•Fever•Pain or swelling in arms or legs•Liver problems•Lower platelets (34%)•Diarrhea (33%)•Vomiting (29%)•Headache (27%)•Constipation (25%)•Hair loss (25%)•Cough (24%)•Rash (24%)•Back pain (24%)•Lower blood sugar (20%)Note: Side effects listed above were reported in studies where people took Kisqali (ribociclib) with another hormone medication.
Common Side Effects forEarly breast cancer
•Lower white blood cell counts (up to 97%)•Lower red blood cell counts (47%)•Higher liver enzymes (up to 45%)•Infections (37%)•Higher creatinine levels (33%)•Lower platelets (28%)•Headache (23%)•Nausea (23%)•Tiredness (22%)Advanced or metastatic breast cancer
•Lower white blood cell counts (up to 94%)•Lower red blood cell counts (72%)•Higher liver enzymes (up to 53%)•Infections (46%)•Nausea (46%)•Tiredness (36%)•Lower platelets (34%)•Diarrhea (33%)•Headache (29%)•Hair loss (29%)•Vomiting (29%)•Back pain (25%)•Constipation (25%)•Cough (24%)•Rash (22%)•Higher creatinine levels (20%)•Stomach pain (20%)Warnings of Kisqali vs. Kisqali Femara Co-Pack
Common Side Effects for•Lung problems•Severe skin reactions•Heart rhythm problem (QT prolongation)•Liver problems•Low white blood cell counts•Harm to unborn babyCommon Side Effects for•Lung problems•Severe skin reactions•Heart rhythm problem (QT prolongation)•Liver problems•Low white blood cell counts•Harm to unborn babyPrices with our coupons for Kisqali vs. Kisqali Femara Co-Pack
Compare other Breast Cancer drugs
Browse medications
View AllResearch prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.